We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Baxter Intnl. | LSE:BAX | London | Ordinary Share | COM STK $1 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.00 | - |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Mar 2020 to Mar 2025
The European Medicines Agency Friday recommended approval of a third swine flu vaccine.
The agency said Celvapan from Baxter International Inc. (BAX) should be granted marketing authorization by the European Commission.
Commission approval is expected shortly, the agency said.
The European Medicines Agency Sept. 25 recommended approval of swine flu vaccines from GlaxoSmithKline PLC (GSK.LN) and Novartis AG (NOVN.VX).
Company Web site: www.emea.europa.eu
-By Jason Douglas, Dow Jones Newswires; 44-20-7842-9272; jason.douglas@dowjones.com
1 Year Baxter Intnl. Chart |
1 Month Baxter Intnl. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
